Overview
IONS market data
Price History
IONS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.32 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -64.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $40.37 – $86.74 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $9.3B · P/B 26.20 · P/S 10.61.
Company News
Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?The Motley Fool · Aug 14, 2026, 2:01 PM
Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?The Motley Fool · Aug 3, 2026, 8:15 PM
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $76Benzinga · Aug 3, 2026, 3:32 PM
Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock TanksBenzinga · Jul 30, 2026, 6:36 PM
Wells Fargo Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $95Benzinga · Jul 30, 2026, 2:18 PM
Microsoft To Rally More Than 40%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · Jul 30, 2026, 12:14 PM
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $115Benzinga · Jul 30, 2026, 10:38 AM
Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease PortfolioBenzinga · Jul 29, 2026, 5:36 PM
8-K filing — IONIS PHARMACEUTICALS INC (IONS)SEC EDGAR · Jul 29, 2026, 11:31 AM
Ionis Pharmaceuticals Affirms FY2026 Sales Guidance of $875.000M-$900.000M vs $895.148M EstBenzinga · Jul 29, 2026, 11:07 AM